cough variant asthma
Conditions
Interventions
Group 1:budesonide/formoterol (Symbicort) 160/4.5ug 2 inhalation bid* 3 months
Group 2:budesonide/formoterol (Symbicort) 160/4.5ug 1 inhalation bid* 3 months
Sponsors
Second Affiliated Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Sign and date the informed consent form indicating that they understand the purpose of and procedure required for the study and are willing to participate in the study; 2. Outpatients aged 18 to 70 years old; 3. Newly diagnosed as CVA, based on symptom and confirm by pulmonary function test according to China asthma guideline 2016 and China cough guideline (2015). Chronic cough(=8 weeks) without wheeze symptoms and signs, often worse at night and (or) in the early morning, often triggered by exercise. Pulmonary function test must meet one of the following three, suggesting a variable airflow limitation and as a basis for lung function diagnosis of asthma: 1) Positive of bronchial challenge test; 2) Positive of bronchodilation test (both FEV1 increased> 12% and FEV1 absolute increase> 200 ml after inhalation of bronchodilator); 3) Excessive variability in twice-daily PEF over 2 weeks: average daily diurnal PEF variability>10%, or average weekly diurnal PEF variability>20%; 4. CSS (cough symptom score, daytime + nighttime) = 3 points.
Exclusion criteria
Exclusion criteria: 1. Participated in any interventional clinical trial during the last 90 days; 2. Accompany with pregnancy; 3. Associated with a clear history of lung diseases such as COPD, bronchiectasis, pulmonary infection, pulmonary interstitial disease, pulmonary hypertension, etc; Or combined with other systems severe illness like cardiovascular, metabolic, immunological, neurological, urinary and blood diseases which may affect the normal conduct of this study; 4.An abuse history of alcohol or narcotic drug, or have a mental history, confrontation personality, adverse motives, suspicious or other emotional or intellectual problems that may affect the informed validity of the study; 5. With a history of upper respiratory tract infection acute exacerbation within 4 weeks before enrollment; 6. Clinical abnormalities associated with symptoms in chest radiology; 7. Smokers; 8. On medications of ACEI or ARB; 9. Not suitable for study observation judged by investigators.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| proportion of CVA patient with symptom relief; | — |
Primary
| Measure | Time frame |
|---|---|
| proportion of CVA patient with symptom relapse; | — |
Countries
China
Contacts
Public ContactWen Li
Second Affiliated Hospital, Zhejiang University School of Medicine
Outcome results
None listed